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Summary 
 
Dendritic cells (DCs) as the professional representatives of antigen presenting cells 
(APCs) play a pivotal role in stimulating the immune system. They present processed 
antigens bound to major histocompatibility complex (MHC) class I or II to CD8+ 
cytolytic T cells (CTLs) or CD4+ T cells, respectively. In an immature state DCs 
(immature DCs, iDCs) are found resting in peripheral tissues where they induce 
tolerance against self-antigens. iDCs become activated by exposure to pathogen 
associated molecular patterns (PAMPs) or inflammatory cytokines and shift from a 
tolerance inducing to an immune activating phenotype. A unique function of DCs is 
that they can cross-present exogenous antigen to CTLs. This signal triggered by 
CD40L, expressed on activated CD4+ T helper cells, is called licensing signal. In 
tumour immunology the activation of tumour antigen-specific CTLs is an important 
step toward tumour rejection. 
Dendritic cells (DC) matured in vitro by Toll-like receptor (TLR)-4 engagement with 
lipopolysaccharide (LPS) show a dynamic phenotype, initially conferring immune 
stimulation followed by immune regulation/suppression. This is indicated by an early 
secretion of interleukine (IL)- 12, the key cytokine for T helper type 1 (Th1) 
polarisation and CTL activation, followed by release of the immune regulatory 
cytokine IL-10. In preliminary experiments it was demonstrated, using DNA micro 
array technology, that these phenotypic and functional characteristics may be 
modulated by CD40/CD40L signalling. We investigated the effect of lentiviral transfer 
of CD40L or GFP control into DCs 6 hours (semi matured, smDC) or 48 hours (fully 
matured, mDC) after maturation with LPS/IFN-γ. Mature DCs that had exhausted 
their capacity for cytokine secretion were re-induced to secrete IL-12 upon CD40L 
but not GFP gene transfer. Importantly, IL-10 secretion remained undetectable. In 
allogeneic mixed leukocyte reactions (alloMLR), mDCs expressing CD40L triggered 
strong CD8+ T-cell proliferation accompanied by an accumulation of Granzyme (GrB), 
a marker for cytotoxic activity. From these data we conclude that CD40L signalling 
rescues an immune stimulatory Th1 DC phenotype in TLR-4 pre-activated mDCs. 
These findings may impact on the rational design of DC-based cancer vaccines. 
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Zusammenfassung 
 
Die Aktivität des Immunsystems wird von dendritischen Zellen (Dendritic Cells, DCs) 
reguliert, die eine zentrale Position an der Schaltstelle zwischen angeborener und 
erworbener Immunität einnehmen. DCs befinden sich in ihrer unreifen Form in allen 
Geweben wo sie Selbstantigene prozessieren und gegen diese Toleranz 
aufrechterhalten. Wurde jedoch ein Ausreifungsprozess in den DCs durch die 
Einwirkung von entzündlichen Zytokinen oder durch das Erkennen von Pathogen 
assoziierten molekularen Mustern (pathogen associated molecular patterns, PAMPs) 
in Gang gesetzt verschiebt sich ihre Funktion von Toleranzauslösung zu 
Immunaktivierung. Dabei verstärkt sich die Fähigkeit von DCs prozessiertes an 
Haupthistokompatibilitätskomplex (major histocompatibility complex, MHC) Klasse I 
oder II gebundenes Antigen an naive T Zellen zu präsentieren. DCs besitzen die 
einzigartige Funktion nach einem zusätzlichen Aktivierungsstimulus exogenes Antigen 
an CTLs kreuz-präsentieren zu können. Dieses Signal, das durch die Bindung an von 
aktivierten Helfer-T Zellen exprimiertes CD40L an DCs vermittelt wird, ist als 
„Lizensierungs-Signal“ bekannt. Die Aktivierung von Tumorantigen-spezifischen CTLs 
ist ein zentraler angestrebter Schritt in der anti-Tumor Vakzinierung. 
In vitro differenzierte DCs, die weiters mit Lipopolysaccharid (LPS) als Toll-like 
Rezeptor (TLR)-4 Ligand ausgereift wurden, zeigen einen dynamischen Phänotyp der 
kurzzeitig nach der Reifung immun-stimulatorisch, später jedoch immun-regulatorisch 
oder suppressiv wirkt. Als Indikator dient dabei die Expression des Helfer T Zell Typ 1 
(Th1) polarisierenden Interleukins (IL)-12. Dieses wird während der immun-
stimulatorischen Phase von DCs sekretiert, wohingegen später die Expression von  
IL-10 regulatorisch auf eine Immunreaktionen wirkt. Wir untersuchten den Effekt von 
ektopisch exprimierten CD40L auf DCs, das durch einen lentiviralen Gentransfer in 
6 Stunden (reifende DCS, semi-mature DCs, smDCs) oder 48 Stunden LPS/IFN-γ vor-
gereifte DCs (reife DCs, fully mature DCs, mDC) eingebracht wurde. Reife DCs, deren 
IL-12 Expression bereits erschöpft ist konnten mittels CD40L, aber nicht mittels GFP 
Gentransfer zur IL-12 Expression re-stimuliert werden. In einer Ko-Kultur von CD40L 
exprimierenden mDCs mit T Zellen eines anderen Spenders konnte beobachtet 
werden, dass vermehrt CTLs mit einer verstärkten lytischen Kapazität, gemessen 
durch Granzyme-B (GrB) Expression, expandiert sind. Daraus schließen wir, dass das 
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durch CD40L vermittelte Signal an DCs den immune-stimulatorischen Phänotyp 
verstärkt. Diese Beobachtungen haben einen starken Einfluss auf das zukünftige 
Design von DC-basierender anti-Tumor-Vakzinierung.  
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alloMLR  Allogeneic mixed 
   lymphocyte  
   reaction 
APC   Allophycocyanin 
APCs   Antigen presenting 
   cells 
CD   Cluster of  
   differentiation 
CFSE   Carboxyfluorescein 
   succinimidyl ester 
CTL   Cytotoxic  
   T lymphocyte 
DAPI   4’,6-Diamidino-2-
   phenylindole 
DC   Dendritic cell 
ELISA   Enzyme linked 
   immunosorbent 
   assay 
FACS   Fluorescent  
   activated cell 
   sorter 
FITC   Fluorescein  
   isothiocyanate 
FoxP3   Forkhead box 
   protein 3 
GFP   Green fluorescent 
   protein 
GM-CSF  Granulocyte  
   monocyte colony 
   stimulating factor 
 
IFN   Interferon 
iDC   Immature DC 
IL   Interleukin 
LC   Langerhans cell 
LPS   Lipopolysaccharide 
mDC   Mature DC 
PAMP   Pathogen  
   associated  
   molecular pattern 
PBMC   Peripheral blood 
   mononuclear cells 
pDC   Plasmacytoid DC 
PE   Phycoerythrin 
PerCP   Peridinin  
   chlorophyll protein 
PI   Propidium iodid 
preDC   Precursor of DC 
smDC   Semi-mature DC 
TAP   Transporter  
   associated with 
   antigen  
   presentation 
Th   T helper cell 
Th1/Th2  T helper cell type 
   1/2 
TLR   Toll like receptor 
TNF   Tumor necrosis 
   factor 
7-AAD   7-Amino- 
   actinomycin
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1 Introduction 
 
1.1 Dendritic cells and the immune system 
 
Multicellular organisms evolved diverse defence mechanisms against pathogenic 
invaders. As soon as infection is detected the innate immune system becomes 
activated. Innate immunity acts in a non-specific manner and represents the first 
barrier for hostile pathogens in the body. Its responses to pathogens reduce infection 
and activate components of adaptive immunity. In detail, it activates antigen-
presenting cells (APCs) that are needed to trigger adaptive immunity and increase 
the specificity of the immune reaction to further on generate memory [5]. 
Dendritic cells (DC) as the main APCs in the body play a pivotal role in the 
stimulation of the immune system [6]. Depending on maturation status DCs can act 
tolerogenic or as main stimulators of immune reactions. Immature DCs (iDCs) reside 
at pathogen-entry sites surveying the surroundings for potential danger for the body 
like inflammation or tissue damage and continuously sample the antigenic 
environment [2]. At this activation state iDCs induce tolerance against self antigens. 
To detect bacterial or viral infection DCs express toll like receptors (TLRs) that 
recognise pathogen associated molecular patterns (PAMPs). These PAMPs are small 
molecular motives that can be found in bacterial or viral surface proteins, which were 
termed by Matzinger and colleagues danger signals [7]. Upon maturation by TLR 
mediated signals indicating infections [8] or injured self phenotypical changes arise 
in the DC, like changes in the expression of adhesion molecules, homing receptors, 
strong up-regulation of T-cell co-stimulatory molecules CD80 and CD86 and 
increased expression of processed antigen bound to major histocompatibility complex 
(MHC). During migration to the lymph node these phenotypic changes, which include 
expression of the T helper type 1 (Th1) polarizing cytokine interleukin (IL)-12 [9], 
develop. After this early phase of activation the DC again shifts its phenotype, 
indicated by exhaustion of the ability to secret Interleukin (IL)-12 [10] and 
immunosuppressive feedback mechanisms start to outweigh the immune stimulatory 
potential of DCs (Figure 1).  
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DCs were first identified by the German anatomist Paul Langerhans in 1868. He 
discovered one DC subset located in the skin, called Langerhans cells (LC). 
Unfortunately, he mistook them for nerve endings [6]. Nearly 100 years later DCs 
were rediscovered by Ralph M. Steinman and colleagues, who purified them from 
murine lymphoid organs and realized that DCs are part of the immune system [1]. 
Since then DCs were intensively studied for their key function as mediators of 
immune reactions. 
  
 
 
1.2 Differentiation of DCs from precursor cells 
 
1.2.1 General information 
 
DCs are comprised of subsets that differ from one another in terms of location, 
antigen presentation and maturation [11-13]. All DC subsets arise from precursor 
cells that are located in the bone marrow [14]. DCs are found circulating in the blood 
and take up residence in fully differentiated but immature form in organs like skin, 
spleen, lung or mucous membranes [6]. In elevated numbers DCs can be found at 
 
L  
Figure 1|Plasticity of the phenotype of DCs: Tolerogenic phenotype is shown until DCs 
encounter maturation stimulus (indicated by red arrow). During the first phase of maturation, DCs 
start to up-regulate co-stimulatory molecules. Confering high immune stimulatory capacity the 
DCs express Interleukin (IL)-12, but after 48 hours DCs have exhausted their capacity for IL-12 
secretion. In our model, immune suppressive mechanisms start to become up-regulated by the 
DC after an early phase of immune stimulation indicated by IL-12 expression.  
days 
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sites of inflammation [15]. As DCs are known to have several roles in the immune 
system like interacting with T cells, B cells and natural killer (NK) cells, all these 
functions can not be carried out by one single cell type. Therefore different subsets 
of DCs are expected to have different functions [2]. There are two models that might 
explain the appearance of different DC subsets in the murine and the human system. 
One is that different functions reflect diverse differentiation stages of one DC lineage. 
The idea behind this model is that the functional differences are entirely depending 
on local environmental signals [2]. The other model suggests that specialized DC 
subtypes represents differentiated DCs from different cell lineages [2]. It is assumed 
that in reality both models exists and interfere to some extent [2]. There are many 
subtypes of DCs described in the murine system. However, this introduction will 
focus on human DCs only. 
 
1.2.2 Human DCs subtypes 
 
In contrast to the murine system where matured DCs can be isolated in vitro out of 
spleenic tissue, in the human system mainly immature DCs (iDCs) or precursors of 
DCs (preDCs) can be found in the blood. These precursors of DCs are called 
monocytes. In vitro the monocytes may be differentiated into DCs with granulocyte-
macrophage colony-stimulating factor (GM-CSF) and interleukin (IL)-4 [16]. 
 
Generally spoken two different DC subsets have been identified yet: myeloid DCs and 
plasmacytoid DCs (pDCs). pDCs, but not myeloid DCs, express toll like receptor (TLR) 
7 and 9 and therefore can detect single stranded (ss) RNA and DNA viruses [17, 18]. 
Further on precursors of pDCs lack T cell receptor alpha (TCRα), TCRβ , TCRγ , TCRδ 
and CD3 chain but express CD4 surface molecules [19]. After maturation by viral or 
bacterial stimuli pDCs express large amounts of alpha/beta interferons (IFN-α/β) and 
thus are identified as “natural type I IFN-producing cells” in the blood [19-21]. These 
two DC subsets arise from haematopoietic precursor cells in the bone marrow 
through yet not fully characterized intermediates to more differentiated precursor 
cells (preDC) circulating in the blood until these cells up-regulate homing receptors to 
peripheral non-lymphoid tissues where they reside as immature DCs (Figure 2) [18]. 
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Though human and murine DCs cannot be compared because they lack the same 
kind of surface molecules (like CD8 as a typical murine DC surface molecule) one 
major DC subset can be found in both individuals as offspring of bone marrow 
precursor cells by differentiation through the myeloid pathway: the langerhans cells 
(LC) that typically express langerin [2]. LCs as typical APCs are located in the skin 
where they remain in an immature state until they get activated. After activation they 
leave the periphery of the body and travel to the lymph node where they stimulate 
naive T cells with processed antigen presented on MHC molecules. Intense studies 
on LC caused the DC-migration-paradigm [22], which postulates that after migration 
DCs start to leave the periphery and travel to the draining lymph nodes. In contrary, 
recent studies showed that also iDCs are found in secondary lymphoid tissues. 
Therefore migration capacity does not automatically mean maturation [22]. Huang 
 
Figure 2|Pathways of DC differentiation: DCs arise from 
haematopoietic stem cells by two lineages: lymphoid or myeloid. 
Endogenous stimuli like cytokines can generate DCs that are matured but 
need further exogenous stimuli to be fully activated. On the other hand 
cytokines also can lead to differentiation but maturation is achieved only 
by further activation with exogenous stimuli like microbial products. 
(pDC1=precursor of DC1) Picture was taken from reference # [2]. 
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and colleagues observed that DCs can be found in lymph nodes bearing fragments of 
apoptotic cells [23]. In vitro studies showed that this DC sub-population stimulates 
allogeneic T cells in mixed lymphocyte reaction (MLR), where DCs and T cells from 
different donors are co-cultivated, but cannot stimulate activation of autologous T 
cells. These migrating iDCs promote tolerance instead [22-24].  
In humans only 0,2 percent of the whole white blood cells are DCs and even less can 
be found in diverse tissues like the skin [6]. 
 
1.3 Maturation 
 
1.3.1 Maturation of DCs in vivo 
 
In the periphery of the body iDCs reside and sample antigen. At this stage iDCs have 
a high potential to capture and process antigen but do not provide any signals for 
T cell activation. In contrary, iDCs trigger tolerance to T lymphocytes in the periphery 
or in case of migrating iDCs, they stimulate T cell deletion or induce regulatory 
T cells. After maturation of the DC triggered by diverse maturation stimuli, the 
function of antigen presentation is up-regulated, detectable by increased amounts of 
MHC class I and II molecules expressed on the cell surface. In parallel,                
T cell co-stimulatory molecules (CD80, CD86) and CD40 are up-regulated and 
expressed on the cell surface. Including IL-12 cytokine secretion, the DC now 
possesses a whole repertoire to prime T cell responses (Figure 6). 
 
Generally, DCs have diverse receptors up-regulated to survey their surroundings. 
One group of receptors that provides the DC with these sensory mechanisms are 
called toll like receptors (TLRs). There are 11 different TLRs known that are 
expressed on human cell types, from which 10 are expressed intracellular or on the 
cell surface of DCs [25]. TLRs recognise PAMPs that are structurally conserved 
molecules derived from microbes. TLR4 is expressed on cell surface of DCs and 
recognizes lipopolysaccharide (LPS), a component of bacterial cell wall. TLR3, TLR8 
and TLR9 are expressed at the endosome or phagosome membrane and recognize 
double stranded RNA (dsRNA), single stranded RNA (ssRNA) or un-methylated CpG 
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DNA motives, respectively. Activation of TLRs in DCs leads to signal transduction by 
translocation of the nuclear factor NF-κB, followed by increased expression of co-
stimulatory molecules and pro-inflammatory cytokines [25, 26]. 
 
DCs can also be matured by inflammatory cytokines like IFN-γ or by interaction of 
CD40L of activated helper T cells (Th) and CD40 of DCs (see also chapter 1.4 the 
licensing signal). In either case phenotypic changes arise in the DC like decreased 
antigen up-take and increased antigen presentation. Also co-stimulatory molecules 
CD80 and CD86 are up-regulated and the DC starts moving towards the lymph node. 
The DC reaches the lymph node at a matured stage and starts to activate antigen 
specific T cells. 
 
 
 
 
 
A B
Figure 6|DCs have different functions depending on their activation status: This model 
from Banchereau and Palucka shows that immature DCs in the steady state can take up antigen 
from apoptotic cells and migrate without maturation into the lymph node (A). Without additional co-
stimulatory signals the DC presents antigen to naïve T cells and leads to deletion of T cells or 
induces regulatory T cells. (B) Mature DCs show increased immunogenicity. In case of infection the 
DCs mature and migrate in large numbers to the lymph node. They present antigen-MHC complexes 
combined with co-stimulatory molecules to naive T cells and induce expansion of antigen-specific 
CTLs, T helper cells, B cells and also regulatory T cells to control the immune reaction. With the 
whole repertoire of adaptive immunity the infection can be eliminated. 
ADCC=Antibody dependent cell-mediated cytotoxicity, also called opsonisation. CTL=cytotoxic 
T lymphocyte. Treg=regulatory T cell. Picture is taken from reference #[3]. 
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1.3.2 TLR4/IFN-γ matured DCs are used as anti-tumour vaccine 
 
As DCs play a central role in controlling immunity they are a logical targets in many 
clinical situations that involve T cells [15]. There are different factors why DCs are 
used as anti-tumour vaccines: at first they activate and expand a whole repertoire of 
tumour-antigen specific effector cells (NK T cells, NK cells, αβ T cells and βδ T cells) 
and second ex vivo generated DCs retain their immunising capacities in cancer 
patients [13, 27]. Though there are many ways to trigger ex vivo generated DCs with 
maturation stimuli, I will only go into detail describing DCs used by our group [28]. 
We generate immature DCs (iDCs) from monocytes derived by elutriation, which are 
differentiated for 6 days with IL-4 and GM-CSF. These iDCs are then loaded with 
whole tumour cell lysate for 2 hours and afterwards are triggered by LPS/IFN-γ as 
maturation stimulus. Before maturation the DCs phagocytose the tumour proteins 
from the culture medium, process them and present them in MHC context on the cell 
surface. After 6 hours maturation (semi-matured DCs, smDCs), up-regulation of co-
stimulatory molecules on the DC surface takes place. Now equipped with antigen 
presented on MHC (signal 1) and co-stimulatory molecules CD80 and CD86 (signal 2) 
for efficient T cell stimulation the DCs moreover expresses IL-12, which is triggered 
by LPS/IFN-γ maturation. Now 3 signals including expression of Th1 polarising 
cytokine IL-12 can be delivered to naïve T cells by injecting these smDC into the 
patient’s lymph node. After completion of a phase I study using these kind of 
antigen-loaded smDCs [28] a phase II trail just recently started. 
 
1.4 Licensing signal 
 
As safety mechanism, cytotoxic T lymphocytes (CTLs) are generally inactive and 
need a further activation signal to develop killing capacity [29]. To trigger killing 
capacity, not only antigen bound to MHC class I is needed to be recognised by CD8+ 
T cells but also additional help for activation from T helper (Th) cells is required. 
These Th cells have to be activated by the same antigen bound to MHC presented on 
an APC. Two models exist that suggest different applications of this licensing signal 
to CD8+ T cells. 
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One model was first described by Keene and colleagues and postulates that Th cells 
and CTLs recognise the specific antigen simultaneously on the same APC [29, 30]. 
The rare event that one APC binds to antigen specific CTL and Th cell provides first 
evidence that there have to exist alternatives. The second model, also called 
“licensingl”-model, was first described in literature as an alternative to general 
knowledge based on theoretical background of Matzinger and colleagues [29, 31, 
32]. In this model it is suggested that DCs as specialized professional APCs present 
exogenous antigen and are activated by a specific signal provided from Th cells. 
These fully activated “licensed” DCs then can stimulate CTLs [29, 33]. In detail, 
CD40L from activated Th cells and CD40, expressed on DC cell surface after 
maturation, are the two molecules responsible for this second activation signal on 
DCs [29, 34, 35]. This model also suggests that the rare event of APCs binding to 
antigen-specific T cells can occur sequentially not simultaneously. 
 
1.5 Interaction of dendritic cells with T cells 
 
1.5.1 Antigen presentation 
 
In most tissues, DCs are present in an immature state. At this state they are unable 
to activate T cells because iDCs fail to have T cell co-stimulatory molecules and do 
not express stimulatory cytokines. Although iDCs lack these requisite accessory 
signals for T-cell activation they are extremely well equipped to capture antigens 
[15]. iDCs take up proteins by phagocytosis or by formation of large pinocytic 
vesicles (macropinocytosis) [9] and by receptor mediated endocytosis [36]. After 
antigen uptake, which also can provide signals for maturation, the DCs loose their 
ability to capture antigen but gain the ability to present antigen associated in major 
histocompatibility complex class I and II (MHC I and II) [15]. To be presented the 
antigen has to be processed into small peptide ligands for MHC molecules by the 
intracellular degradation machinery of the DCs. 
 
There are two main ways of antigen degradation in DCs dependent on the source of 
antigen. Antigens can be characterized as endogenous, which means located in the 
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Figure 3|Antigen presentation 
by MHC class I pathway of DC: 
Endogenous antigen like self 
antigen or viral proteins are 
processed by the proteasome and 
loaded on MHC class I in the 
endoplasmatic reticulum (ER, 
indicated as blue lumen). 
MHC class I molecules then are 
exported using the golgi apparatus 
(indicated as green) to be 
expressed on the cell surface. 
Picture taken from reference # [1] 
cytosol of the DC, or exogenous, that are products from other cells that are up-taken 
from the surroundings by the DC [1]. The peptides presented by MHC class I 
molecules are derived from proteins degraded mainly in the cytosol by the 
proteasome (Figure 3), whereas MHC class II molecules present peptides that are 
derived from proteins degraded in endosomal compartments by the cathepsins and 
other hydrolytic enzymes (Figure 4) [37]. 
 
1.5.1.1 Presentation of endogenous antigen on MHC class I molecules 
 
All cells in the body have the ability to process defective ribosomal products or 
proteins by degradation using the proteasome. 
After degradation the processed antigen is 
transported into the lumen of the endoplasmatic 
reticulum (ER) using the transporter associated with 
antigen presentation (TAP). In the ER lumen freshly 
synthesised MHC class I molecules are retained. 
The imported processed antigens are then loaded 
on MHC class I molecules and expressed on the cell 
surface (Figure 3).  
In case of viral infection the virus uses the protein 
production machinery of the host to synthesise all 
viral specific proteins that are needed for 
replication. These proteins also are degraded by the 
proteasome-degradation-pathway and are 
presented on MHC class I molecules. T cells that 
traffic the tissue looking after patterns that are not 
derived by the body itself can recognise these viral 
protein-MHC class I complexes. The T cell then kills 
the target cell to evade on-going infection and 
multiplication of viral particles. 
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Figure 4|MHC class II pathway 
of antigen presentation by DC 
Exogenous antigen is uptaken and 
processed by the endocytic 
degradation route. Peptides are 
then loaded on MHC class II 
molecules and presented on cell 
surface. Picture taken from 
reference # [1]
1.5.1.2 Presentation of exogenous antigen on MHC class II molecules 
 
In contrary to the MHC class I pathway exogenous antigens are presented on 
MHC class II molecule following another pathway of degradation [4]. In this pathway 
exogenous antigen or self-antigen that is processed by the endocytic pathway is 
degraded by different proteases, like cathepsins. Small Peptides are formed as 
intermediates during late endosomal protein degradation. The loading of 
MHC class II molecules during this endocytic route is triggered by the chaperone 
protein HLA-DM and antigen-MHC complexes are then transported to the cell surface 
(Figure 4) [4, 38]. Also self-antigens that are found in endosomal compartments of 
DCs are presented on MHC class II molecules [1]. This includes components like 
particles of the endocytic pathway, recycled membrane proteins and peptides derived 
from autophagy [1, 37, 39].  
Antigen loaded on MHC class I or class II can be recognised by the T cell receptor 
(TCR) of naïve T cells in the lymph node, in 
detail CD4+ helper T cells bind antigen loaded on 
MHC class II molecules, whereas CD8+ CTLs 
only detect antigen-MHC class I complexes. 
Recognition alone can not activate T cells but 
further binding of co-stimulatory molecules from 
DCs to CD28 molecules expressed on the surface 
of T cell is needed. During maturation the DCs 
start to migrate into the lymph node and up-
regulate not only processed antigen in MHC 
context but also CD80 and CD86 for T cell co-
stimulation (see also chapter 1.6. Effector 
functions of DCs). 
 
1.5.2 Cross presentation 
 
To stimulate CD8+ T cells against antigens that 
are not expressed by the DC (e.g. tumour 
antigens or antigens derived from viruses that do 
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not infect DCs), exogenous antigen has to be presented by DCs in MHC class I 
context. This antigen presentation pathway differs from the classical presentation of 
exogenous antigens, which are normally bound to MHC class II molecules [4]. This 
process is called cross-presentation. As cross-presentation is likely to activate CTLs in 
response to vaccine antigens it is a intensively studied mechanism but not very well 
understood by now. Different suggestions exist for this switch of MHC molecule class 
(Figure 5). 
 
Figure 5|Different models of cross-presentation: Classical presentation of intracellular 
antigens is restricted to MHC class I molecules. Intracellular antigen are processed by the 
proteasome or peptidases and transferred into the endoplasmatic reticulum (ER) using the 
transporter associated with antigen presentation (TAP). In the lumen of the ER newly synthesized 
MHC class I molecules are loaded with the antigen and presented on the cell surface. For cross-
presentation exogenous antigens enter this classical MHC class I route in different ways.  
(A) Peptides from neighbouring cells can be directly transferred to the cytosol of DCs using gap 
junctions.  
(B) Also recycling of MHC class I molecules can lead to re-load by exogenous antigen in 
endosomes.  
(C) Fusion of compartments from the phagosomal route and the ER lead to transfer of uptaken 
exogenous antigen into the lumen of the ER.  
(D) Antigens can also leave the endosome using export mechanisms into the cytosol.  
(E) Exosomal derived antigens can bind to DC surface and be up-taken.  
Picture is taken from reference # [4] 
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Figure 6|DC activates T helper cell: The matured 
DC stimulates T helper cells by application of 3 signals: 
At first, antigen presentation (interaction of TCR and 
MHC), second co-stimulation with CD80/CD86 binding 
to CD28 and as signal 3 it polarises T cell development 
by secretion of polarising cytokines. 
Neiijssen and colleagues showed that intracellular peptides can be transferred from 
one cell to neighbouring monocytes by using gap junctions (Figure 5A) [40]. Studies 
also showed that extracellular proteins enter the cytosol of DCs and make them 
available for proteasomal degradation. This is then followed by transport to the ER 
using transporter associated with antigen presentation (TAP) and presentation on the 
cell surface after loading to MHC class I molecules in the lumen of the ER (Figure 5E, 
C, D) [41-43]. Gromme and colleagues observed that MHC class I molecules can be 
recycled from the cell surface and may load exogenous antigen during recycling by 
the endocytic pathway (Figure 5B) [4, 44]. 
 
1.6 Effector functions of DCs 
 
Mature DCs are defined by their ability to trigger T cell stimulation by delivering three 
different signals [22]. Directly, these three signals define the specific T cell effector 
function that is polarized after activation by DCs [45]. 
 
1.6.1 Signal 1 - Antigen presentation 
 
Signal 1 is derived from TCR binding to antigen-MHC complex presented by DCs. This 
signal alone cannot induce T cell stimulation. Without further activation signals the 
DCs inactivate naive T cells and induce 
tolerance. (As described in chapter 1.5.1 
antigen presentation) 
 
1.6.2 Signal 2 - Co-stimulation 
 
Signal 2 is the additional signal triggered 
by co-stimulation of T cells by the DC 
that, together with signal 1, induces 
immunity. Co-stimulation is performed 
by binding of CD28 on T cell surface to 
CD80/CD86 expressed by DCs [22, 46]. 
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Signal 2 makes the decision if tolerance or an immune response takes place, as not 
only T cell stimulatory molecules like CD28 can be bound but also cytotoxic T-
lymphocyte antigen 4 (CTLA4) shows high affinity to CD80/CD86, that further on 
leads to tolerogenic or suppressive signals [22, 47, 48]. CTLA4 is only expressed on 
activated T cells [49] and signal transduction by CTLA4 stimulates suppressive 
effects. 
 
1.6.3 Signal 3 – The polarisation signal 
 
Signal 3 was recently added to the terminology and describes signals from DCs that 
trigger the differentiation of stimulated T cells to effector cells [22, 50]. After antigen 
presentation on MHC complexes to TCR, co-stimulatory signals by CD80/CD86 
binding, an additional cytokine-secretion profile as signal 3 is important to raise 
antigen specific effector functions in T cells. These cytokines mediate immunity 
against pathogens infecting the host. 
 
Th1 cells secrete IFN-γ, and tumour necrosis factor-α to raise cellular immunity 
against intracellular bacteria or viral infection [51]. 
Th2 cells activate humoral immunity against extracellular parasites by producing 
Interleukin (IL)-4, IL-5 and IL-13 [51]. The DC delivers again one critical signal to 
prime immune responses by activating T cell effector functions as it expresses the 
Th1 polarising cytokine IL-12 [52]. Recent data suggests that INF-γ, provided by a 
third cell (presumably NK cells, or γδ T cells), beside IL-12 is critical for Th1 
polarisation [53]. On the contrary, without IL-12 expressed from DCs mast cells, 
NK T cells, basophils, eosinophiles and again γδ T cells produce IL-4 and support Th2 
polarisation [51]. 
 
Together these 3 signals provided from matured DCs give rise to multiple types of T 
cell differentiation including immunity, tolerance and immune evasion [22]. 
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1.7 Working hypothesis 
 
In in vitro experiments one always tries to model the in vivo situation. In our DC 
model we mature DCs by administration of lipopolysacharide (LPS) and 
interferon gamma (IFN-γ) to resemble a bacterial infection (Figure 1). During 
bacterial infection TLR4 is stimulated in vivo by LPS and additionally IFN-γ is 
supplemented by the activated innate immunity as key pro-inflammatory cytokine. 
Early after maturation, when IL-12 is highly expressed by DCs, the DC is called semi-
mature (smDC). After some time DCs get fully matured (mDCs) and highly up-
regulate phenotypic maturation molecules but IL-12 expression is terminated. At this 
maturation stage DCs are called “exhausted” for their ability to secrete IL-12. In the 
in vivo situation, maturing DCs reach the lymph node and stimulate Th cell 
proliferation by interaction of antigen loaded MHC II (exogenous antigen) with the 
TCR/CD3 complex under additional co-stimulation by the B.7 family molecule 
members (e.g. CD80 and CD86). CD40 that is up-regulated on the surface of mature 
DCs then interacts with CD40L of Th cell and triggers cross-presentation. After this 
licensing signal the DC is able to express exogenous antigen in MHC class I context, 
a mechanism that is still not fully clarified. Yet the DC can present antigens derived 
from viruses or tumour by phagocytosis to CD8+ T cells and activate them by co-
stimulation.  
We postulated the following working hypothesis: By ligation of ectopically expressed 
CD40L on DCs to CD40 (Figure 7) we can administer an additional maturation signal 
to fully matured IL-12 exhausted DCs. These “exhausted” DCs can then be re-
activated by a second wave of IL-12 expression triggered by CD40-CD40L ligation. 
Up-coming negative regulatory feedback mechanisms are diminished by the immune 
stimulatory capacity of the re-activated DC. Exogenous antigen then can be 
presented to CTLs and further on Th1 polarised T cell stimulation is induced 
(Figure 7). After activation and expansion of antigen specific CTLs the infection in the 
periphery can be eliminated. 
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This model implies that fully matured DCs are able to receive a second activation 
stimulus which extends their capacity to act as immune stimulators. In our model, 
this immune stimulation is IL-12 dependent and can be re-induced in DCs with 
exhausted capacity for IL-12 expression by CD40-CD40L ligation. This concept is 
controversial as most investigators consider DCs terminally differentiated with 
exhausted capacity for IL-12 expression after one single maturation stimulus and the 
resistance to any further maturation signal. 
1.8 Specific aims 
 
The aim of my project was to investigate the function of CD40L ectopically expressed 
on DCs to further understand the impact of CD40L as a critical part in our model of 
two step maturation. This model suggests that DCs at peripheral infection sites are 
matured by PAMP engagement and pro-inflammatory cytokines mimicked in our in 
vitro DC maturation strategy by LPS and IFN-γ supplementation. After migration into 
the lymph node the DCs receive a second CD40-CD40L derived signal ligation and 
thus develop into professional APCs with the ability to cross-present exogenous 
LPS
iDC
1.)
TLR4
lv-CD40L
CD8+ T cell
auto stimulationCD40
CD40L
IL-12
cross stimulation
p-mDC
2.)
3.)
4.)
3.)
 
Fig 7|CD40L gene transfer into pre-matured DCs by lentiviral transduction: iDCs 
are matured by TLR4 activation with LPS (1) and immediately afterwards transduced with 
lentiviral particles containing genetic information for CD40L expression. In co-culture with T 
cells, the CD40L expressing DC (2) can now stimulate itself by CD40-CD40L interaction or 
cross stimulate other DCs (3). CD40-CD40L interaction delivers the licensing signal to DCs 
which then present exogenous antigen in MHC I context and activate CD8+ T cells. 
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antigen and prime CTLs. CD40L was directly expressed on LPS/IFN-γ activated DCs 
in order to investigate the cytopathic effects of lentiviral transfer. The effect of 
CD40L expressed on DCs at different maturation stages (smDCs and mDCs, as 
described in chapter 1.3.2. TLR4/IFN-γ matured DCs are used as anti-tumour 
vaccine) was determined by measuring phenotypic alterations of the DCs including 
cytokine secretion and T cell stimulatory potential in an allogeneic setting. 
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2 Material and Methods 
 
2.1 Primary Cells and Cell Lines 
 
2.1.1 Dendritic cells 
 
Leukocytes were collected using an Amicus leukocyte apheresis device (Baxter, 
Deerfield, IL) from healthy volunteers. For the enrichment of monocytes from PBMCs 
in the leukocyte apheresis product the Elutra cell separator (Gambro BCT, Lakewood, 
CO) was used by following the instructions of the manufacturer. Basically, the cells 
are separated by sedimentation velocity, dependening on cell-size and density. After 
separation the cells were analysed by flow cytometry, by labelling the cells with 
monoclonal antibodies directed against CD3, CD4, CD8, CD19, CD14, and CD15 
(antibodies from BD Pharmingen, San Diego, CA) in order to detect total T-
lymphocytes, T-helper cells, cytotoxic T-lymphocytes, B-lymphocytes, monocytes, 
and granulocytes, respectively. Labelled cells were analysed on a FACSCalibur flow 
cytometer (Becton Dickinson, Mountain View, CA) and data analysis was performed 
using CellQuest software (Becton Dickinson, Mountain View, CA). If not stated 
otherwise, the same data analysis software and FACS flow cytometer was used in all 
further settings. 
 
2.1.1.1 Differentiation 
 
Monocytes, enriched from the isolation process by elutration described above were 
differentiated by following a previously optimised protocol for generating DCs [54]. 
In detail, monocytes were cultured at a starting density of 1x106 monocytes/cm2 in 
CellGro medium supplemented with 1000 U/ml recombinant human GM-CSF and 
300 U/ml recombinant human IL-4 (all from CellGenix, Freiburg, Germany) at 37°C 
and 5 % CO2 for 6 days. On day 3 the cells were fed with the same volume of 
CellGro plus GM-CSF and IL-4. 
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2.1.1.2 Maturation 
 
Maturation was carried out on day 5 or day 7, depending on experimental setup, by 
adding 50 ng/ml IFN-γ (Boehringer Ingelheim, Vienna, Austria) and 1000 ng/ml 
lipopolysaccharide (LPS, E. coli strain O111:B4, Calbiochem, San Diego, CA, USA) to 
the culture for 6 hours to generate semi-mature (sm) DCs, or continuously for 
48 hours to generate fully-mature (m) DCs. In case of lentiviral transduction the cells 
were washed after 6 hours or 48 hours and transduces with lentiviral supernatant in 
presence of 50 ng/ml IFN-γ and 6 µg/ml hexadimethrine bromide (Polybrene; Sigma-
Aldrich, St. Louis, MO) for another 6 hours. For detailed information see also chapter 
2.4.2 Lentiviral transduction of DCs. 
 
2.1.2 Peripheral Blood Mononuclear Cells (PBMCs) 
 
Peripheral blood mononuclear cells (PBMCs) were isolated from Buffy Coat, obtained 
from healthy blood donors at the blood bank of General Hospital Vienna by 
centrifugation over Ficoll PaqueTM PLUS density gradient (Amersham Biosciences, 
Uppsala, Sweden). PBMCs were collected from interphase after centrifugation at 
665xg at 20°C for 20 minutes and washed twice with 1x D-PBS (Invitrogen, Grand 
Island, NY), total cell number was assessed by SYSMEX KX-21 CBC analyzer (Sysmex 
Deutschland GmbH, Norderstedt, Germany) and cells were resuspended in AIM-V 
medium (Invitrogen Corporation, Bethesda, MD) with 2% pooled human AB plasma 
(Octaplas, OP, Octapharm, Vienna, Austria)(AIM-V/OP). Cells were frozen at -80°C in 
portions of 5x107 cells in freezing medium, consisting of 40% AIM-V/OP, 40% OP 
and 20% DMSO (Dimethylsulfoxid, SERVA, Heidelberg, Germany). After freezing the 
cells were stored in liquid nitrogen until further use. 
 
2.1.2.1 Purification of CD3+ T cells 
 
To have a detailed look at the proliferation potential of CD4+ and CD8+ T cells in   
co-culture with CD40L expressing DCs (CD40L-lv-DC), CD3+ T cells were isolated 
from PBMCs by cell depletion based on magnetic bead cell sorting using a pan T cell 
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isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany). PBMCs isolated from 
Ficoll density gradient centrifugation were thawed at 37°C water bath and 
immediately diluted in AIM-V/OP for further washing steps. Standard centrifugation 
velocity was 483xg at 4°C for 7 minutes. If not stated otherwise, these settings were 
used for all cell types. Isolation of CD3+ T cells by negative depletions means indirect 
labelling of all CD3- non T cells with biotin-conjugated antibodies directed against 
CD14 (macrophage marker), CD16 (NK cells), CD19 (B cell marker), CD36 (platelet 
marker), CD56 (NK cells), CD123 (plasmacytoid dendritic cell and basophilic 
granulocyte marker) and CD235a (Glycophorin A, erythroide cell marker). These 
antibodies then bind to anti-biotin magnetic beads which are retained in a column 
placed into a magnetic field. After two washing steps all untouched CD3 purified T 
cells were flushed through the column and collected in flow-through. Aliquots before 
and after depletion were compared to calculate purity of CD3+ T cells. 
2.1.2.2 Proliferation assay using CFSE labelling of CD3 purified T cells 
 
After two washing steps with 1x D-PBS the CD3 purified T cells were resuspended in 
1x D-PBS, 0,1 %BSA at concentration of 1x107 cells/ml and labelled with 5 μM 
Carboxy-fluorescein-succinimidyl ester (CFSE; Invitrogen Corporation, Bethesda, MD) 
for 10 min at 37°C with slight shaking every 2 min. Cells were then re-covered by 
addition of 10 times the volume OP to D-PBS,01 %BSA solution and incubated for 
5 min at RT. CD3 purified CFSE labelled cells were then washed using AIM-V, 2%OP 
and number of lymphocytes was measured using SYSMEX KX-21 CBC analyzer 
(Sysmex Deutschland GmbH, Norderstedt, Germany) if not stated otherwise. 
Proliferation was measured by CFSE-dilution in context of an allogeneic mixed 
lymphocyte reaction (alloMLR, see chapter 2.1.2.3 Allogeneic Mixed Lymphocyte 
Reaction). 
 
2.1.2.3 Allogeneic Mixed Lymphocyte Reaction (alloMLR) 
 
CD3+ CFSE labelled T cells were co-cultivated in total volume of 200 µl AIM-V/OP in a 
96 well round bottom plate at density of 105 cells/100µl/well together with 
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stimulating allogeneic DCs at a 1:3, 1:9 and 1:27 DC : T cell ratio. The DCs were 
TLR4 pre-matured for either 6 hours (smDC) or 48 hours (mDC) with LPS/IFN-γ at 
concentrations described above and both groups were transduced with lentiviral 
particles, containing genetic information for CD40L or GFP (lvCD40l or lvGFP, 
respectively), or left untreated (nolv; see also chapter 2.4.2 Lentiviral transduction of 
DCs). As control for the proliferation capacity of CD3+ cells the T cells were co-
cultivated with cocktail mixture of staphylococcal exotoxins A and B (SEA/SEB; Toxin 
Technology Incorporation, Sarasota, FL) at concentrations of 200 ng/ml. To show the 
background proliferation potential of un-stimulated CD3+ cells the T cells were 
incubated with AIM-V/OP only. On day 6 50 µl of supernatant was collected and 
frozen at -20°C for cytokine analysis by Flow Cytometric Bead Array (Bender Med 
Systems, see below) and cells were harvested and fixed with Cytofix/Cytoperm (BD 
Pharmigen). The proliferation and activity potential of CD4+ and CD8+ T cells was 
measured by CFSE dilution in dividing cells and CD25 positivity. For analysis of 
cytolytic activity of CD8+ T cells intracellular granzyme B (GrB) expression was 
measured. GrB is the key component of the cytotoxic lymphocyte granules that can 
trigger an apoptotic caspase cascade in target cells [55]. Cells were then analysed 
for proliferation determining absolute number or percentage of CFSE negative cells 
(see chapter 2.2. Flow cytometry). 
 
2.1.3 HeLa 
 
The HeLa cell line is derived from an aggressive glandular cervical cancer [56]. After 
thawing the cells at 37°C, the cells were kept in 1650 RPMI (Euroclone, Milan, Italy) 
supplemented with 10 % FCS (PAA, Pasching, Austria) and split at stages of 80 -
100 % confluence. The cells were detached by applying 1/10 of the original culture-
volume Accutase (PAA, Pasching, Austria) for 15 minutes. 
 
2.1.4 293FT 
 
The 293FT cell line (Invitrogen Corporation, Bethesda, MD) is derived from the 293F 
cell line [57] and stably expresses the SV40 large T antigen from the 
pCMVSPORT6TAg.neo plasmid. Expression of the SV40 large T antigen is controlled 
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by the human cytomegalovirus (CMV) promoter and is high-level and constitutive. 
Usage of 293FT Cell line allows generation of lentiviral constructs by co-transfection 
of plasmids containing genetic information of packaging and reverse transcriptase 
function (see chapter 2.4.1 Production of lentiviral particles). 
293FT cells were cultivated in DMEM (Gibco, Invitrogen, Carlsbad, CA) supplemented 
with 10 % FCS, 0,1mM MEM Non-Essential Amino Acids, 2mM L-glutamine (PAA, 
Pasching, Austria) and 500 µg/ml geneticin (Invitrogen Corporation, Bethesda, MD) 
and passed when they were over 80 % confluent after incubation with Accutase. 
 
2.2 Flow Cytometry 
 
To measure the maturation status of DCs, GFP or CD40L expression after lentiviral 
gene transfer and proliferation of T cell subsets in alloMLR, cells were analysed using 
FACS flow cytometry. 105 cells were harvested and FC receptors were blocked with 
µg human purified Ig (Sandoglobulin) for at least 15 min at 4°C to reduce unspecific 
immunofluorescent staining. Surface antigens of interest were then detected with 
antigen specific fluorochrome-conjugated monoclonal antibodies for 30 min at 4°C. 
 
2.2.1 Surface staining 
 
Phenotype of DCs after maturation was determined by measuring surface molecule 
densities CD80, CD86, CD83, MHC I and MHC II (Table 1). To determine purity of 
CD3 depleted lymphocytes cells were analysed with anti-CD45, anti-CD14, anti-CD3 
and anti-CD56 antibodies to detect amount of un-depleted cells. 
 
2.2.2 Intracellular staining 
 
Proliferation of T-cells after alloMLR were analysed for surface expression of CD3, 
CD4, CD8, and CD25. Intracellular molecules like Granzyme-B or FoxP3 transcription 
factor were detected by intracellular staining using Cytofix/Cytoperm fixation kit (BD 
Pharmingen, San Diego, CA). After staining of cells surface antigens cells were fixed 
by application of 250 µl Fixation/Permeabilization solution for 20 min at 4°C. Two 
Material and Methods  Romana Luger 
22 
washing steps with 1x BD Perm/Wash solution were performed prior to application of 
anti-Granzyme B (all from BD Pharmingen, San Diego, CA) and anti-FoxP3 
(eBioscience) antibodies. After final washing step with 1xPBS 3-5x104 cells were 
acquired for determining total cell number with Trucount system techniques or 
percentage of CFSE negative cells using FACS Calibur or FACS LSRII flow cytometer 
and data analysis was performed with FACS CellQuest or FACS DIVA software (all 
purchased from Becton Dickinson, Mountain View, CA). Viability of cells was 
measured with propidium iodide (Pi), 7-aminoactinomycin (7-AAD) or 4’,6-diamidino-
2-phenylindole (DAPI). All appropriate isotype control antibodies were included in 
analysis. 
 
Label Fluor chrome Company Clone 
anti-CD3 PE-TR/APC BD Pharmingen /SK7 
anti-CD4 PerCP BD Pharmingen SK3 
anti-CD8 APC-Cy7 BD Pharmingen SK-1 
anti-CD14 FITC DAKo TÜK4 
anti-CD25 Alexa Fluor 647 Serotec MEM-181 
anti-CD40L PE BD Pharmingen TRAP1 
anti-CD45 PerCP BD Pharmingen Hle-1 
anti- CD56 PE BD Pharmingen NCAM 16.2 
anti-CD80 PE Immunotech MAB104 
anti-CD83 APC BD Pharmingen HB15e 
anti-CD86 FITC BD Pharmingen 2331 
anti-MHC I PE DAKO W6/32 
anti-MHC II FITC DAKO CR3/43 
anti-granzymeB Alexa Fluor 700 BD Pharmingen GB11 
anti-Vδ2 PE BD Pharmingen B6 
anti-FoxP3 APC eBioscience PCH101 
Table 1|Antibodies used for flow cytometry 
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2.3 Cytokine Detection 
 
2.3.1 Enzyme linked immunosorbent assay (ELISA) 
 
Supernatant of DC cultures were analyzed 48 hours after maturation with LPS/IFN-γ 
at standard concentrations (see DC maturation) or lentiviral transduction with 
lvCD40L or lvGFP for IL-12 and IL-10 expressions using conventional Enzyme linked 
immunosorbent assay (ELISA) two-sandwich technique. 
One 96-well plate (Nunc Maxisorp, Roskilde, Denmark) was coated overnight at 4°C 
with appropriate capture antibody diluted to final concentration in 1x D-PBS with 
0,02% sodium azide (Merk, Darmstadt, Germany). The other day the plate was 
washed using ELISA-Washers (Skan Washer 400, SCATRON), followed by 
administration of 250 µl 2% bovine serum albumin (BSA; Sigma-Aldrich, St.Louis, 
MO) diluted in 1x D-PBS per well for 3 h for blocking reaction, evading unspecific 
binding to Fc receptors (FcR). After blocking, standard solutions of known 
concentration ranging from 62,5 ng/ml to 4000 ng/ml IL-10 or IL-12 protein and 
diluted samples were distributed in duplicates into the wells and incubated over night 
at RT. 
 
Table 2|Antibodies used for ELISA 
 
The next day one washing step was followed by application of biotinylated detection 
antibody (Table 2; BD PharMingen, San Diego, CA) After incubation for 4 h at RT 
phosphatase conjugated streptavidin SA110 (Chemicon International, CA) was added 
in concentrations of 1:1000 in 1xD-PBS/1%BSA per well for 1h at RT. During this 
incubation step Sigma 104 DNPP phosphatase substrate tablets (Sigma Diagnostics, 
St. Louis, MO) were dissolved in diethanolamin buffer (1 tablet/5 ml buffer) and 
100 µl were administered into every well. The plate was incubated in the dark until 
colour change was detected. The adsorption of the enzyme reaction was measured 
at 405-690 nm using a microtiter plate reader (Anthos Labtec Instruments, Salzburg, 
cytokine capture-AB conc detection-AB conc 
IL-12 anti-human IL-12p70 2 µg/ml Biotin anti-human IL-12p40/p70 50 ng/ml 
IL-10 anti-human IL-10 0,5 µg/ml Anti-human IL-10 50 ng/ml 
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Austria). Analysis was performed with Anthos WinRead software (Anthos Labtec 
Instruments, Salzburg, Austria). 
 
2.4 CD40L gene transfer 
 
2.4.1 Generation of lentiviral particles 
 
Using ViraPower™ Lentiviral Expression System (Invitrogen, Carlsbad, CA) replication 
incompetent HIV-based lentiviral particles were generated. This gene transfer system 
can be used to deliver and express a gene of interest into non-dividing mammalian 
cells. As described in the manufacturer’s manual the lentiviral cDNA is reverse 
transcribed once inside the cell and stably integrates into the genome using long 
terminal repeats (LTRs). Diverse modifications in the genetic material of the virus 
guarantees replication incompetence and high biosafety. By co-transfection of 293FT 
producer cell line with pLP-plasmids encoding for viral structural proteins, polymerase 
and reverse transcriptase (pLP/VSVG, pLP-1, pLP-2) and pLenti6/V5-plasmids 
containing GFP or CD40L at the multiple cloning sites lentiviral particles were 
generated. In preliminary projects the human CD40L cDNA was amplified from pcDL-
SRalphahCD40L by PCR and cloned in pLenti6/V5-D-TOPO vector (Figure 8). 
Seventytwo hours after co-transfection the supernatant was harvested and 100-fold 
up-concentrated by ultracentrifugation. Ultracentrifugation was performed using 
Sorvall RC 5C PLUS superspeed centrifuge and fixed angle TFT 8013 rotor(Sorvall 
Products, L.P. Newtown, Connecticut, USA) at 103 600xg, at 4°C for 90 minutes, 
resuspended in CellGro and stored at -80°C until further use for maximum 6 month. 
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2.4.2 Lentiviral transduction of DC 
 
48 h and 6 h pre-matured DCs were transduced with lentiviral particles (250 µl 100x 
concentrated lentiviral supernatant/1x106 DC) in combination with 6 µg/ml Polybrene 
(Sigma-Aldrich,) plus IL-4, GM-CSF and IFN-γ in standard concentrations. In detail 
DCs were harvested after maturation with Accutase and washed once with D-PBS. 
For transduction with lentiviral particles 1x106 DC were centrifuged and supernatant 
was completely removed. DCs were resuspended in lvCD40L or lvGFP and 
supplemented with IL-4, GM-CSF, Polybrene and IFN-γ at standard concentrations. 
The cells were then transferred to a 48-well plate and incubated for 6 hours at 37°C 
at 5 % CO2. After lvCD40L/lvGFP transduction the cells were detached with cell 
aggregate disociation medium (Accumax, Innovative Cell Technologies Inc., San 
Diego, CA) by application of the same volume Accumax to DC culture for 20 minutes 
at 37°C, washed and exact cell number was assessed by TruCount system. Then 
cells were used for alloMLR and separately cultured at concentration of 
1x106 cell/cm²/ml with IL-4, GM-CSF and IFN-γ at standard conditions. For IL-12 and 
IL-10 quality control supernatant was taken 24 h after transduction with 
lvCD40L/lvGFP and expression of GFP/CD40L and phenotypic markers CD80, CD86 
and MHC II were measured after 48 h following standard procedures. 
Figure 8|Co-transfection of 293FT producer cell line with three packaging 
plasmids (pLP1, pLP/VSVG, pLP2) and pLenti6/V4 plasmid containing CD40L or GFP 
cDNA leads to formation of lentiviral particles in the supernatant of 293FT cell culture.  
CD40L cDNA
293 FT virus containing 
supernatant
co-transfection
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2.4.3 Datamining lentiviral titer 
 
HeLa cell line was used to assess lentiviral titer by plating 5x105 cells in 6-well plates 
for 12-15 hours and then transduced with 10-2 to 10-10 dilutions of lentiviral 
supernatant in RPMI, 10 % FCS in presence of 6 µg/ml Polybrene. Fourtyeight hours 
after transduction with lentiviral particles the culture medium was supplemented with 
2 µg/ml Blasticitin (Invitrogen Corporation, Bethesda, MD to test for antibiotic 
resistance after transduction. Medium was changes every 1 – 2 days. During the next 
3 weeks transduced single cells grow under selective pressure to colonies which 
could be stained by application of Türks solution (Merck, Darmstadt, Germany) 
directly to cell lawn for 10 min at 4°C, followed by two washing steps with 1xPBS and 
count to establish an average Transforming Unit (TU). All tested lentiviral 
supernatants comprised TUs between 7,5x105 to 6x105. 
To assess the multiplicity of infection (MOI, defined as the number of viral particles 
infecting one cell) in lentiviral supernatants different TU – cell number ratios were 
tested by transfection of 6 h pre-matured DCs, resulting in MOI of 0,2, that was used 
in all further transfection procedures. 
The titer obtained with HeLa cells used is expected to be approximately 10-fold lower 
than the titer obtained when using HT1080 cells that were recommended to use from 
the manufacturer (Invitrogen, ViraPower Lentiviral Expression System, instruction 
manual). 
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3 Results 
 
3.1 Mature DCs show improved T cell co-stimulatory function 
and secrete IL-12 
 
DCs were differentiated from monocytes which are derived from aphaeresis products 
by density centrifugation (Elutration) during culture over 6 days in CellGro medium 
supplemented with IL-4 and GM-CSF. Compared to adherence, elutriation generates 
DC precursor cells with a higher percentage of CD14+ cells and increased IL-12 
secretion from mDCs [58]. 
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Figure 9|Maturation status of mature DCs compared to immature DCs: DCs were 
generated from monocytes by differentiation with IL-4 and GM-CSF during 6 days cell culture. 
After differentiation DCs were left untreated (iDC) or matured with LPS/IFN-γ for 6 hours (smDC). 
Cytokines release in supernatant was analysed 24 hours after maturation, surface molecule expression of 
DCs was measured 48 hours after maturation. (A) Expression pattern of surface molecules 
determined by flow cytometric analysis is shown. Compared to iDCs (upper panels) mDCs show 
up-regulation of CD80, CD86, CD83, slight increase in MHC I and II expression and down-
regulation of CD14. (B) Shows cytokine expression profile of smDCs measured 24 h after 
triggering maturation with LPS/IFN-γ. Supernatant was analysed for IL-10 and IL-12 expression 
using ELISA technique. mDCs show increased expression of IL-12 and IL-10 compared to iDCs. 
One representative experiment out of 10 is shown. 
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Figure 10|LV titer: HeLa cells transduced with 
different dilutions of lentiviral supernatant (LV-
N°7) under selective conditions using blasticidin 
during 4 weeks cell culture are shown. Blue spots 
represent colonies with integrated blasticidin 
resistence gene located on pLenti6-V4 vector. 
Mock indicates un-transduced HeLa cells. TU of 
8x105 was generated using LV-N°7, as one 
representative experiment out of 3. 
After differentiation, DCs were matured with TLR 4 ligand Lipopolysaccharide (LPS) 
and the pro-inflammatory cytokine IFN-γ. Maturation for 6 hours generated semi-
mature DCs (smDCs) with a peak expression of IL-12, whereas maturation for 
48 hours generated fully matured DCs (mDCs), which have exhausted their capacity 
for IL-12 secretion. After activation of DCs the maturation status was measured by 
detection of the co-stimulatory molecules CD80, CD86, the activation marker CD83, 
CD1a, MHC I, MHC II and CD14a expressed on the surface of smDC and mDC 
48 hours after treatment with LPS/IFN-γ using flow cytometric analysis (Figure 9A). 
Additionally, 24 hours after maturation (in detail: 6 hours maturation followed by 
18 hours culture in normal culture medium) samples were taken from smDC 
supernatant and accumulated amounts of expressed IL-12 and IL-10 were measured 
by ELISA. We observed up-regulated expression of the Th1 polarising cytokine IL-12 
after maturation with LPS/IFN-γ with the peak expression after 24 hours but also 
expression of the immune suppressive cytokine IL-10 (Figure 9B). 
 
3.2 Lentiviral gene transfer system efficiently infect primary 
cells and cell lines leading to ectopic expression of CD40L 
 
Lentiviral particles were produced by 
co-transfection of the 293FT producer 
cell line with plasmids encoding the 
structural packaging proteins, reverse 
transcriptase and the transgenes 
CD40L or GFP-control (see Figure 8, 
chapter 2.4.1. Generation of lentiviral 
particles). After 72 hours the 
supernatant was harvested and 
100 times concentrated by 
ultracentrifugation. Prior to lentiviral 
transduction of DCs the titer was 
assessed by infection of the HeLa cell 
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line with different dilutions of lentiviral supernatant. HeLa cells were plated at 50 % 
confluency. The next day, lentiviral supernatant was diluted 10-2 to 10-10 in RPMI 
supplemented with 10 % FCS and administered to adherent HeLa cells. Forty-eight 
hours after transduction, the medium was changed and fresh RPMI, 10 % FCS 
supplemented with 2 µg/ml blasticitin was added. After four weeks of cell culture 
under selective conditions single cells grew to colonies, which then were counted to 
obtain the number of transforming units (TU) in every lentiviral batch tested 
(Figure 10). To define the optimal transduction protocol with sufficient transgene 
expression in DCs as target cells, different multiplicities of infection (MOI) were 
tested. Therefore, 0,5x106 and 1x106 mDCs were treated with 250 µl viral 
supernatant (MOI of 0,4 and 0,2, respectively) supplemented with IL-4, GM-CSF and 
IFN-γ. As recommended in the manufacturer’s manual we used hexadimethrine 
bromide (Polybrene) to enhance the transduction of lentivirus into DCs. Six hours 
after the transduction, CellGro medium supplemented with IL-4, GM-CSF and IFN-γ 
was added to the DC culture to the total volume of 1 ml/1x106 DCs/cm². 
Supernatant was taken 24 hours after the transduction to determine the amount of 
cytokines expressed, whereas the expression of the transgene GFP/CD40L and the 
maturation status of DCs was measured 48 hours after transduction. Fifteen to 90% 
of viable lvCD40L-DCs showed expression of CD40L compared to un-transduced DCs 
with MOI=0,4 and MOI=0,2. The percentage of dead cells increased with enhanced 
MOI, but the percentage of GFP/CD40L positive cells remained equal (data not 
shown). Hence we used MOI=0,2 in CellGro culture medium supplemented with IL-4, 
GM-CSF, IFN-γ and Polybrene for further experiments. 
 
3.3 Lentiviral transduction did not affect expression of DC 
phenotype markers 
 
After generating lentiviral supernatant by co-transfection of the 293FT producer cell 
line and 100 times concentration, the titer was determined using negative selection 
of transduced HeLa cells. SmDCs were then transduced to compare GFP/CD40L 
expression of different lv-production batches and different monocyte-donors. To 
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Figure 11|CD40L/GFP Expression: DCs were 
matured 6 hours or 48 hours with LPS/IFN-γ. Matured 
DCs then were transduced for 6 hours with lentiviral 
supernatant using MOI=0,2. Expression of CD40L or 
GFP on the surface of mDCs and smDCS was measured 
48 hours after transduction. Blank histograms show 
CD40L/GFP expression of CD40L or GFP transduced 
DCs. Filled histograms show the transgene expression 
of matured transduced but unlabeled DCs. For 
transduction we used LV N°7; one representative out of 
5 experiments is shown. 
compare the effect of lentiviral transduction and CD40L interaction on DCs with 
different maturation status we used differently pre-matured DCs. 
After differentiation for 6 days with IL-4/GM-CSF, dendritic cells were matured by 
exposure to LPS/IFN-γ for 6 hours or 48 hours to generate smDCs and mDCs, 
respectively. After maturation, 
the cells were washed and 
resuspended in lentiviral 
supernatant (250µl lvCD40L or 
lvGFP/1x106 c, MOI=0,2) 
supplemented with IL-4, GM-
CSF, IFN-γ and Polybrene. 
Control groups were handled 
the same way, including 
centrifugation steps, but left 
un-transfected (no-lv). After 
24 hours, aliquots were 
analysed for IL-12 and IL-10 
production, after 48 hours cells 
were harvested and analysed 
by flow cytometry for surface 
expression of phenotypic 
maturation markers. Ectopic 
expression of the transgene CD40L or GFP was measured 48 hours after transduction 
(Figure 11). The ectopic expression profile of the transgene did not show significant 
differences depending on the length of maturation. For reasons of enhanced auto-
fluorescence after maturation and transduction, lvCD40L-DC were used as control for 
GFP expression and the other way round.  
The maturation status was determined by measuring the expression of the co-
stimulatory molecules CD80, CD86 and CD83 of lentivirally transduced DC. Compared 
to the control groups, no significant further up-regulation of phenotypic maturation 
molecules was observed due to lentiviral transduction or CD40/CD40L interaction 
(Figure 12). 
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We observed a full maturation status in mDCs with enhanced up-regulation of CD83 
compared to smDCs. No further up-regulation of CD80 and CD86 was observed in 
mDCs compared to smDCs. MHC I and II surface molecule expression on lentivirally 
transduced smDCs and mDCs were also compared with appropriate control, but we 
observed no difference (data not shown).  
 
 
 
3.4 Rescue of Th1 related cytokine expression by CD40L 
 
The cytokine expression profile provides first evidence for the high potency of CD40L 
as inducer of immune stimulatory cascades: although the IL-12 and IL-10 cytokine 
expression was increased in smDCs due to lentiviral transduction, mDCs did not 
respond to lentiviral gene transfer alone. Lentiviral gene transfer into 6 hours pre-
matured DCs (smDCs) induced a boost of IL-12 and IL-10 cytokine expression 
compared to un-transduced DC control groups. Unlike smDCs expressing GFP, the 
ectopic expression of CD40L on smDCs further triggered an increase in IL-12 and   
IL-10 expression. Interestingly, mDCs, which are known to be exhausted in terms of 
cytokine expression, could be re-activated to express IL-12 using lv-CD40L, but no 
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Figure 12|Maturation status of lentiviral transduced smDCs and mDCs: Maturation 
phenotype of 6 hours pre-matured and 48 hours pre-matured DCs after lentiviral transduction 
is shown. Filled histograms reflect fluorescence intensity (FI) of phenotypic markers CD86, 
CD80, CD83 of untransduced iDCs, whereas blank histograms show FI of phenotypic surface 
molecules 48 hours after transduction of smDCs and mDCs with lvCD40L and lvGFP. DCs were 
pre-matured for 6 or 48 h with LPS/IFN-γ and subsequent transduction was performed for 6 h 
with Polybrene and IFN-γ supplemented. One representative experiment out of 9 shown. 
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expression of IL-10 was shown. Control DCs transfected with lentiviral particles 
containing genetic information to express GFP did not show re-expression of 
cytokines in terminally differentiated (mDCs) (Figure 13, lower diagram). The 
cytokine expression was measured 24 hours after the start of transduction of pre-
matured DCs. These data are in agreement with preliminary data where co-cultures 
with CD40L expressing cell lines were performed (Dohnal et al.; unpublished 
observations) provides evidence that CD40L can trigger Th1 polarised second step 
maturation of DCs.  
 
3.5 Negative depletion increased purity of CD3+ T cells 
 
CD40L expressing DCs were generated in two different ways: first, smDCs were 
transduced with lv-CD40L which led to increased expression of IL-12 and IL-10 (lv-
smDC); on the other hand, exhausted mDCs were transduced with lv-CD40L and 
thus re-activated for IL-12 expression (lv-mDC). To analyse the T cell stimulatory 
potential of these lv-DCs compared to un-transduced DCs, allogeneic mixed 
lymphocyte reactions (alloMLR) were performed. DCs and T cells from different 
Figure 13|Cytokine secretion pattern: (A) and (B) show IL-
12 and IL-10 secretion, respectively, of smDCs and mDCs 
compared to iDCs and transduced DCs. (A) IL-12 expression was 
re-initiated by lvCD40L transduction of cytokine exhausted mDCs, 
whereas (B) shows that no IL-10 was further expressed after 
lvCD40L treatment of mDCS. Amount of cytokines was measured 
by ELISA 24 h after transduction. Cytokine amounts below the 
detection limit are indicated by asterisks. One representative 
experiment out of 4 is shown. 
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donors (allogeneic) were co-cultured for 6 days and afterwards activation and 
proliferation of different T cell subsets was analysed. AlloMLRs were set in DC:T cell 
rations from 1:3, 1:9 and 1:27 to cover a broad spectrum of the stimulation capacity 
of DCs. Since we were interested in proliferation of CD4+ or CD8+ T cells as main 
effector cells stimulated by DCs in the immune system, we focused on these two 
subsets by CD3+ purification from whole peripheral blood mononuclear cells 
(PBMCs). To enrich CD3+ T cells, we made the decision to use negative depletion, 
which means that CD3+ target cells stay untouched and are not activated by CD3 
crosslinking. Contaminating cell populations were indirectly magnetically labelled and 
retained in the magnetic columns leading to generation of highly pure CD3+ T cells. 
 
Before and after depletion the cells were analysed by flow cytometry and the 
percentage of CD3+ T cells was compared to the percentage of contaminating non-
T cell populations like monocytes, macrophages, B cells, natural killer (NK) cells, and 
erythroid cells (CD14, CD16, CD19, CD36, CD56, CD123 and CD235a) was compared. 
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Figure 14|CD3 purified T cells used for allogeneic mixed lymphocyte reaction 
(alloMLR): PBMCs were indirectly magnetically labeled and retained to magnetic field 
by using anti-CD14, CD19, CD36, CD56, CD123 and CD235a antibodies (A) Distribution 
of cells on the basis of cell size (FSC) and granulation (SSC) is shown before and after 
CD3 purification. (B) Percentage of contaminating cell polulations is shown compared to 
negative un-labeled control. Reduction of CD56+ NK cells and CD14+ monocytes was 
achieved by negative depletion of PBMCs. Data analysis was performed using flow 
cytometric analysis. One representative experiment out of 7 is shown. 
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The amount of CD3+, CD56+ NK cells and CD14+ monocytes left after depletion is 
shown in Figure 14. 
 
The distribution on the basis of cell size (forward scatter, FSC) and granulation 
(sideward scatter, SSC) shows the whole cell population before and after depletion 
and indicates the retained non-T cell populations after effective CD3 purification 
(Figure 14A). The percentage of CD14+ cells in the post-depletion sample indicates 
that nearly all monocytes were retained in the column and the total amount of 
monocyte contamination was reduced to 0,2 % CD14+ of total cells (Figure 14B). 
The amount of CD56+ cells was decreased from 13% in PBMCs to 0,7 % of total 
cells. We obtained a purity of 97 % CD3+ T cells (Figure 14B). All CD3 purifications 
performed obtained purities ranging from 71 % to 97 % of CD3+ T cells in total cell 
population (Figure 14 shows one representative out of 7 experiments). 
After purification, CD3+ T cells were labelled using carboxyfluorescein succinimidyl 
ester (CFSE) to measure T cell proliferation. CFSE is taken up by T cells and diluted 
into progeny cells by cell division. Before purifying CD3+ T cells, DCs were 
differentiated from monocytes using IL-4, GM-CSF during 7 days culture. On day 5, 
one part of these DCs was matured by TLR4 ligation with LPS/IFN-γ for 48 hours, the 
other part was LPS/IFN-γ matured on day 7 for 6 hours. After maturation, the cells 
were harvested, washed and transduced with lv-CD40L or lv-GFP at MOI of 0,2 for 
6 hours in CellGro medium supplemented with IL-4, GM-CSF, IFN-γ and Polybrene. 
To evade cluster formation cells were then harvested using cell aggregate 
dissociation medium (Accumax, Innovative Cell Technologies Inc., San Diego, CA) 
and a single cell suspension was re-covered. We observed tight cell-cell contact in lv-
DCs after transduction, which could not be disrupted by conventional Accutase 
treatment or resuspension. 
CD3+ CFSE labelled T cells were then co-cultivated with different lv-DC numbers, 
ranging from 1:1=DC : T cell ratio to 1:27 in alloMLR for 6 days. As control for 
maximum proliferation, CD3+ T cells were incubated with staphylococcal exotoxins A 
and B (SEA/SEB). Background proliferation of T cells was shown in culture medium 
alone. The maturation phenotype, the percentage of ectopically expressed GFP or 
CD40L and cytokine expression was measured as quality control of lentiviral 
transduction. Therefore lentivirally transduced DCs retained after transduction from 
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alloMLR were cultured at final concentration of 1x106 DCs/ml/cm² in CellGro medium 
supplemented with IL-4, GM-CSF and IFN-γ. Supernatant was analysed 24 hours 
after transduction for cytokine expression, maturation phenotype and ectopic 
expression of the transgenes GFP or CD40L after 48 hours. 
 
3.6 LvCD40L-mDC stimulation decreases percentage of T cells 
with intermediate expression of CD25 
 
After 6 days, cells co-cultivated in alloMLR were harvested. Analysis of T cell 
expansion was performed by measuring the percentage of CFSE negative CD4+ and 
CD8+ T cells using flow cytometry. Further on, the proliferation of CD3+, Vδ2+ and 
Granzyme B+ (GrB) T cells was measured. The CD25 surface molecule expression 
indicated the activation status and the possible effector function of T cells.  
 
This activation status of T cell subpopulations was thereby used to discriminate 
between putative T helper (Th) cells as CD4+CD25int and CD4+CD25high regulatory 
T cells (Treg) (Figure 15). After alloMLR we observed the expansion of two 
populations of CD4+ T cells expressing CD25 in different surface densities. For 
detection of expanding activated T cells we analysed CFSE negative CD25+ T cells, 
which generated two populations with high and intermediate amounts of CD25 
expressed on cell surface (CD25high and CD25int, respectively; Figure 15). Cut off 
levels of CD25neg, CD25int and CD25high expression was always compared to 
CD
25
CFSE
n
eg
in
t
h
igh
SEA/SEB PBMCs lv-CD40L mDC lv-GFP mDC mDC
CD
25
n
eg
in
t
h
igh
Figure 15|Discrimination of activated CD4+ T cells by CD25 expression: CD3 
purified T cells were co-cultivated with lentivirally transduced DCs and control un-
transduced DCs in different ratios. 1:27=DC:T cell ratio of alloMLR measured on day 6 is 
shown compared to SEA/SEB positve control and un-stimulated PBMCs only. CD4+ T cells, 
activated with GFP or CD40L expressing mDCs or only mDCs are shown. Lentiviral 
transduction of CD40L compared to GFP indicates different CD25 distributions in total CD4+ 
T cell population. One respective experiment out of 5 is shown.
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appropriate negative (only CD3+ T cells cultured in medium only; PBMCs) and 
positive control (SEA/SEB stimulated CD3+ T cells). 
 
The analysis of alloMLR with lv-CD40L transduced DCs revealed that no significant 
differences between lvCD40L-DC and control groups in stimulation capacity of total 
CD4+ T cell population was observed, neither with 6 hours or 48 hours activation 
stimuli prior to transduction (Figure 16). Repeatedly we observed a tendency that 
CD40L signal on mDCs inhibits CD4+ T cell proliferation compared to GFP expressing 
mDCs or un-transduced mDCs (Figure 16, lower diagram). Furthermore CD4+ T cells 
were analysed based on the activation status by CD25 expression (Figure 16B, 
Figure 16C). In CD4+CD25int cell populations smDCs showed again no significant 
differences after lv-transduction compared to un-transduced DCs, whereas lvCD40L-
mDC appeared to trigger little proliferation of CD4+CD25int compared to control 
groups (Figure 16). Highly activated CD4+CD25high indicated stimulation from 
lvCD40L-mDCs, but lv-smDCs showed less proliferation potential than un-transduced 
control groups (Figure 16A). 
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Figure 16|Proliferation and activation of CD4+ T cells in alloMLR: CD4+ T cells 
stimulated in alloMLR after 6 days with lentiviral transduced GFP or CD40L expressing pre-
matured DCs and control groups are shown. (A) Proliferation of total CD4+ T cells indicate 
tendency of little stimulation potential triggered by lvCD40L-mDC. (B) Percentage of 
CD4+CD25int cell population of total CD3+ T cells is shown. Lv-CD40L transduction decreases 
stimulation potential of mDCs. (C) Percentage of highly activated CD4+CD25high T cells is 
shown. Percentage positve cells increases when stimulated with lvCD40L-mDC compared to 
control groups. One representative experiment out of 5 is shown. (LvCD40L-DC = squares, 
lvGFP-DCs = triangles, untransduced control DCs = diamond) 
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3.7 lvCD40L-mDC enforces lytic capacity of CTLs 
 
The potential of lentivirally transduced CD40L or GFP expressing DCs to stimulate 
T cell activation and proliferation was measured by analysis of CD4+ and CD8+ T cell 
expansion in an alloMLR after 6 days. As general read-out, the proliferation of CD8+ 
T cell in all CD3 purified lymphocytes was measured using CFSE dilution in total CD8+ 
T cells. In contrast to proliferation of total CD4+ T cells (Figure 16A), lvCD40L-mDC 
showed enhanced stimulation capacity in CD8+CFSE- T cell populations compared to 
control groups (Figure 17, lower diagram). Again no significant differences in 
proliferation of CD8+ T cells stimulated by lentivirally transduced smDCs and control 
un-transduced smDCs was observed (Figure 17A, upper diagram).  
 
Effector cell function was measured in CD8+ T cells by expression level of Granzyme 
B (GrB) as a component of cytolytic granules within CTLs (Figure 17B). LvCD40L-
smDCs showed a tendency to increase the percentage of CD8+GrB+ T cells compared 
to control groups, and lvCD40L-mDCs showed significant up-regulation of GrB 
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Figure 17|Proliferation and lysis capacity of CD8+ T cells in alloMLR: Different 
DC to T cell ratios of alloMLR are shown. (A) Percentage proliferating CD8+ T cells 
stimulated by CD40L or GFP expressing smDCs and mDCs compared to un-transduced 
control groups is shown. (B) Percentage of Granzyme B expressing CD8+ T cells is 
shown. (C) Primary data of 1:9 DC:Tcell ratio of lvCD40L-mDCs indicates increased 
expansion of GrB+ CTLs after stimulation with CD40L expressing mDCs in alloMLR. One 
representative experiment out of 5 is shown. (LvCD40L-DC = squares, lvGFP-DCs = 
triangles, untransduced control DCs = diamond) 
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expression up to 2 fold compared to lvGFP-mDC and un-transduced mDC control 
stimulations (Figure 17C). 
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4 Discussion 
 
Based on general immunological principles we set up our working hypothesis. We 
suggest that antigen processing DCs are matured in peripheral tissue by 
encountering so-called danger signals (PAMPs, pro-inflammatory cytokines), start 
migrating into the lymph node where they get in contact with naive T cells in a fully 
formed maturation status. With up-regulated co-stimulatory molecules and 
exogenous antigen bound to MHC II DCs they interact with the TCR and CD28 on 
CD4+ T h cells. These Th cells start to up-regulate CD40L, that further binds to CD40 
expressed on surface of matured DCs. CD40-CD40L ligation induces the second 
maturation step and re-initiates IL-12 cytokine secretion in mDCs, which have 
exhausted their capacity for cytokine secretion [10]. Also CD40-CD40L interaction 
triggers licensing of DCs to cross-present exogenous antigen in MHC I context to 
stimulate CD8+ T cells. The CD8+ T cells now are fully activated to function as 
antigen-specific CTLs. 
 
4.1 Lentiviral transduction as an optimal method for gene 
transfer into resting primary cells 
 
DCs as representatives of resting primary cells are known for the difficulties of gene 
transfer. The literature indicates the need for efficient gene transfer into DCs to alter 
the diverse immune modulatory functions of these APCs as they play pivotal roles in 
the immune system and therefore are interesting targets for medical application 
[13]. Different ways to transfer genetic information into primary not-dividing cells like 
DCs was found in the literature, but side-effects like increased number of apoptotic 
DCs and maturation initiation by using electroporation [59], the need for cell-division 
in retroviral genetransfer or short dated expression of transgene by transfection are 
common. Although transfection of DCs with adenoviral constructs is more often used 
[60-63] it does not result in stable integration into the genome. Therefore alternative 
gene-transfer methods are in demand. With lentiviral particles a continuous 
expression of transgene due to stable integration into host cell genome using long 
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terminal repeats (LTRs) can be obtained. Additionally lentiviral constructs are known 
to transduce resting, un-dividing primary cells [60, 62, 63] and stably express target 
genes. 
To generate more potent Th1 polarising DCs as improvements of next generation 
tumour vaccines the effect of CD40L on DCs was measured by DNA micro array-
based whole genome expression profiling (Dohnal et al., unpublished data) in 
preliminary projects. These data provided first evidence that CD40L acts as second 
maturation stimulus on mDCs after TLR4 activation. CD40-CD40L ligation restores 
the immune stimulatory capacity of terminally differentiated mDCs by re-expression 
of IL-12, which is a key cytokine for Th1 polarisation of immune reactions. We used 
CD40L and GFP expressing plasmids for co-transfection of the producer cell line 
293FT with plasmids containing structural information and reverse transcriptase 
function to obtain lentiviral supernatant. After 100 times up-concentration by 
ultracentrifugation the titer was measured by negative selection of transduced HeLa 
cells. Generation of lentiviral particles showed to be a highly sensitive system with 
different critical points. High purity of plasmids for co-transfection and logarithmic 
growth rate of 293FT producer cell line was pivotal for production of moderate 
amounts of lentiviral particles in supernatant, but still the lentiviral titer generated by 
negative selection comprised 103x less transforming units (TU) than expected. 
Though the manufacturers’ protocol indicates that higher titer numbers may be 
obtained by using HT1080 we only generated TUs of 7-8x105/ml after 
ultracentrifugation and concentration by factor 102 (Figure 9). As multiplicities of 
infection (MOI) values of 0,2 were used to obtain more than 50% of the transduced 
cells positive for transgene expression, the generated TUs are only values for 
comparative evaluation of different lentiviral production series but did not generate 
real number of lentiviral particles per ml. To assess the titer of lentiviral supernatant 
application of the antibiotic Blasticitin was used to select for transduced single cells 
that integrated after transduction a cDNA for antibiotic resistance. This selection 
procedure acts more crucial on HeLa cells with low lentiviral particles integrated and 
thus with less antibiotic resistance. These cells are deleted early after transduction 
and do not grow to colonies. 
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4.2 Maturation reduces sensitivity of DCs to genetic 
manipulation 
 
In preliminary tests we also tried to transduce monocytes with lvCD40L and lvGFP to 
generate 100% CD40L/GFP positive DCs during 6 days differentiation culture under 
selective conditions. Monocytes showed to be very sensitive for lentiviral transduction 
as a number of apoptotic cells increased compared to un-transduced control groups. 
An additional maturation stimulus was triggered by lentiviral transduction prior to full 
differentiation, presumably by early stimulation of TLR3 with free dsRNA, derived 
from the lentivirus construct that resulted in un-specific differentiation to non-DC 
populations (data not shown). 
Also fully differentiated iDCs were transfected with lentiviral supernatant to generate 
CD40L expressing iDCs capable of early stimulation by CD40-CD40L interaction after 
maturation. iDCs were shown to be very sensitive to transduction indicated by high 
loss of cells due to apoptosis, characterized by Pi positive cells after 48 hours post-
transfection (data not shown). Remaining PI negative cells up-regulated CD80, CD86, 
CD83, MHC I and II and secreted IL-12, all of which showed that transfection of iDCs 
alone already had great potential for maturation. In contrast, pre-matured (either 
6 hours or 48 hours LPS/IFN-γ) DCs showed no differences in maturation-dependent 
surface molecule up-regulation compared to control groups. Again, iDCs reacted to 
dsRNA in the cytoplasm, derived from lentiviral based gene transfer. Preliminary DNA 
micro array-based whole genome expression profiling that was performed prior to 
this project in our laboratory already indicated that TLR3 is highly up-regulated in 
DCs in an immature state. It was shown that the TLR4 signal transduction pathway is 
down-regulated after TLR4 induction. After maturation by TLR4 signalling, expression 
of TLR3 and down-stream signal transduction molecules was slightly down 
modulated. 
The maturation of DCs optimised the survival of transduced cells and showed no side 
effects in differentiation. To determine the effect of CD40L on matured DCs we 
compared transduction of 6 hours pre-matured DCs (lv-smDCs) with transduction of 
mDCs (lv-mDCs) after 48 hours LPS/IFN-γ stimulus. Interestingly, the CD40-CD40L 
interaction re-initiated IL-12 expression in mDCs, which produced data that was in 
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conflict with the general paradigm that mDCs are terminally exhausted for their 
capacity to express IL-12 [10]. 
The CD40L interaction after LPS/IFN-γ maturation with highly up-regulated CD40 on 
DCs results in re-initiation of IL-12 expression, depending on the maturation state of 
DCs. This substantiates our working hypothesis that CD40-CD40L interaction occurs 
in vivo after maturation and triggers a second boost of DC-stimulation leading to IL-
12 expression. 
 
4.3 CD40L expressing mDCs highly activate CD4+ T cells but 
lead to the loss of the Th cell population 
 
In our alloMLR the potential of lv-DCs to stimulate T cell proliferation and activation 
was mainly measured by up-regulation of the activation marker CD25 expressed on 
the cell surface of CD4+ T cells and the loss of CFSE fluorescence intensity of cells 
due to division. The general activation status of CD4+ T cell is used to measure the 
effector function, as suppressive T cell populations expressing CD4+ T cell co-
receptor show high amounts of IL-2 receptor molecule CD25 presented on cell 
surface [64].  
The expression of transcription CD25 was measured in CD4+ T cells to identify T cell 
subsets with suppressive or regulatory function. Transduction of mDC with lv-CD40L 
showed increase of CD4+CD25high cell population. 
The detection of the forkhead family transcription factor 3 (FoxP3) expression was 
originally used to identify suppressive Treg cells after in vitro expansion. Recent data 
suggests that FoxP3 acts as activation marker that is transiently up-regulated in 
CD4+CD25high T cells with no suppressive function. Only naturally occurring Treg cells 
show stable expression of FoxP3 [65, 66]. Recent data provide evidence that 
epigenetic modifications of the translational region of the FoxP3 gene locus are 
related to stable FoxP3 expression only in Treg cells [65]. Detection of the FoxP3 
protein is no indicator for suppressive or regulatory function of CD4+CD25high T cells. 
In contrary CD4+ Th and Treg cells can be distinguished by analysis of CD25 
expression (Figure 15). The IL-2 receptor molecule CD25 is highly up-regulated in 
Treg cells whereas activated Th cells only express CD25 in moderate amounts [67]. 
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One function of highly up-regulated CD25 might be that IL-2 as proliferation 
supporting cytokine is depleted from the surroundings by being captured in high 
amounts by CD25 molecules expressed on Treg cells [68]. Another model suggests 
that Treg cells act cell-contact dependent and highly up-regulated CD25 surface 
molecules only indicate expansion triggered by IL-2. The helper or regulatory 
function of CD4+CD25+ populations may only be analysed by the effect of these cells 
on other T cell subsets in co-cultures.  
In alloMLR CD40L expression on mDCs stimulated CD4+CD25high T cell expansion but 
only decreased numbers of CD4+CD25int expressing subpopulations, the later with 
potential Th cell function (Figure 16), were measured. These findings provide first 
evidence that ectopically expressed CD40L on DCs adds the licensing signal for cross-
presentation of exogenous antigens in MHC I context and decreases the need for 
interaction with Th cells in vitro. The binding of CD40 to CD40L, both expressed on 
the DCs themselves, may capture all free CD40 molecules and therefore CD40L on 
activated Th cells can not be bound. This then may lead to decreased Th 
proliferation. Th cell independence has to be investigated by further experiments 
using CD4 and CD8-purified T cells in alloMLR reaction with lvCD40L-mDCs. 
 
4.4 Cytolytic activity of CTLs is IL-12 dependent 
 
The T cell activation analysis of CD8+ CTLs after 6 days of alloMLR reaction was 
performed by measuring decrease of CFSE fluorescence intensity due to proliferation. 
The cytolytic function of CD8+ T cells was analysed by expression of Granzyme B 
(GrB) as key component of cytolytic granules of activated CTLs that is critical for 
T cell receptor-induced cell death [69]. The activation potential of lvCD40L-mDCs in 
alloMLR provided first evidence that IL-12 exhausted mDCs with re-initiation of IL-12 
production due to CD40L transduction have increased CTL priming capacities 
compared to control groups (Figure 17). 
 
We conclude that these findings have the potential to impact on the design of DC 
based cancer vaccines. 
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